翻訳と辞書 |
Catalyst Pharmaceuticals : ウィキペディア英語版 | Catalyst Pharmaceuticals
| operating_income = | assets = | equity = | num_employees = 20 as of March 20, 2015〔 | parent = | divisions = | subsid = | homepage = (www.catalystpharma.com ) | footnotes =〔 Catalyst Pharmaceuticals (CPRX) stock information via Wikinvest.〕〔 Catalyst Pharmaceuticals (CPRX) annual SEC balance sheet filing via Wikinvest.〕 | intl = }} Catalyst Pharmaceuticals is a biopharmaceutical company based in Coral Gables, Florida. The company is developing therapeutics for rare neurological diseases, including Firdapse (3,4-diaminopyridine phosphate, a potassium channel blocker) for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and CPP-115 (a GABA transaminase) for the treatment of infantile spasms.〔Mann Jr., Joseph A. (“The big gamble: Catalyst Pharmaceuticals of Coral Gables bets on new drug for rare disease” ), Miami Herald, 18 July 2015. Retrieved on 26 August 2015. 〕〔Nehamas, Nicholas. (“Catalyst Pharmaceuticals reports second-quarter net loss, plans to submit new drug for FDA approval” ), “Miami Herald”, 11 August 2015. Retrieved on 26 August 2015. 〕 ==History== Founded in 2002, Catalyst Pharmaceuticals competed an IPO in 2006.〔(【引用サイトリンク】title= Catalyst Pharmaceuticals Registration Statement Form S-1 )〕 Catalyst focused primarily on developing therapies to prevent addiction until 2012.
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Catalyst Pharmaceuticals」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|